Lipocine (LPCN) FCF Margin (2018 - 2025)

Lipocine's (LPCN) quarterly FCF Margin came in at 2605.93% in Q3 2025, down 760.5% on a QoQ basis from 302.84% in Q2 2025.

Lipocine (LPCN) FCF Margin (2018 - 2025) Analysis & Trends

Lipocine (LPCN) has 7 years of FCF Margin data on file, last reported at 2605.93% in Q3 2025.

Quarterly FCF Margin changed N/A year-over-year to 2605.93% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 119.12% (down 5298.0% YoY) and the FY2024 annual result came in at 11.71%, up 40498.0% from the prior year.
FCF Margin eased to 2605.93% in Q3 2025, from 302.84% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 939.68% in Q4 2023 to a low of 12692.34% in Q3 2021.
A 5-year average of 2271.46% and a median of 457.08% in 2025 frame the typical range for FCF Margin.
Annual changes were most pronounced in 2024 — FCF Margin jumped 718210 bps — and 2025, when it slumped 212960 bps.
Tracing LPCN's FCF Margin over 5 years: stood at 55.92% in 2021, then tumbled by 1193 bps to 611.33% in 2022, then surged by 254 bps to 939.68% in 2023, then plunged by 95 bps to 48.46% in 2024, then sank by 5478 bps to 2605.93% in 2025.
The last three FCF Margin figures came in at 2605.93% (Q3 2025), 302.84% (Q2 2025), and 2097.99% (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn	-
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn	22.62%
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn	-22.35%
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn	41.07%
9	Royalty Pharma	27.12 Bn	26.28 Bn	-	70.82%
10	Lipocine	11.42 Mn	-12.49 Mn	-	-

Download Data